PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) Stock Fundamental Analysis
EPA:ALPAT - FR0010785790 - Common Stock
9.08 EUR
-0.1 (-1.09%)
ALPAT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 70 industry peers in the Biotechnology industry. ALPAT has a medium profitability rating, but doesn't score so well on its financial health evaluation. ALPAT has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination!
1. Profitability
1.1 Basic Checks
In the past year ALPAT was profitable.
ALPAT had a positive operating cash flow in the past year.
In multiple years ALPAT reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALPAT reported negative operating cash flow in multiple years.
1.2 Ratios
ALPAT's Return On Assets of 5.85% is amongst the best of the industry. ALPAT outperforms 82.43% of its industry peers.
ALPAT's Return On Equity of 9.95% is amongst the best of the industry. ALPAT outperforms 83.78% of its industry peers.
The Return On Invested Capital of ALPAT (1.41%) is better than 75.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.85% | ||
| ROE | 9.95% | ||
| ROIC | 1.41% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALPAT has a better Profit Margin (48.52%) than 97.30% of its industry peers.
ALPAT's Operating Margin of 11.16% is amongst the best of the industry. ALPAT outperforms 82.43% of its industry peers.
The Gross Margin of ALPAT (116.00%) is better than 98.65% of its industry peers.
ALPAT's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.16% | ||
| PM (TTM) | 48.52% | ||
| GM | 116% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.17%
GM growth 5Y-4.76%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALPAT is destroying value.
ALPAT has more shares outstanding than it did 5 years ago.
2.2 Solvency
ALPAT has an Altman-Z score of 0.61. This is a bad value and indicates that ALPAT is not financially healthy and even has some risk of bankruptcy.
ALPAT has a Altman-Z score of 0.61. This is comparable to the rest of the industry: ALPAT outperforms 50.00% of its industry peers.
The Debt to FCF ratio of ALPAT is 1.69, which is an excellent value as it means it would take ALPAT, only 1.69 years of fcf income to pay off all of its debts.
ALPAT has a better Debt to FCF ratio (1.69) than 91.89% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that ALPAT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.19, ALPAT is in the better half of the industry, outperforming 63.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 0.61 |
ROIC/WACC0.19
WACC7.26%
2.3 Liquidity
ALPAT has a Current Ratio of 0.57. This is a bad value and indicates that ALPAT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.57, ALPAT is not doing good in the industry: 83.78% of the companies in the same industry are doing better.
ALPAT has a Quick Ratio of 0.57. This is a bad value and indicates that ALPAT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.30, ALPAT is not doing good in the industry: 87.84% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.3 |
3. Growth
3.1 Past
ALPAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1057.93%, which is quite impressive.
Looking at the last year, ALPAT shows a quite strong growth in Revenue. The Revenue has grown by 14.61% in the last year.
Measured over the past years, ALPAT shows a quite strong growth in Revenue. The Revenue has been growing by 10.44% on average per year.
EPS 1Y (TTM)1057.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.1%
Revenue 1Y (TTM)14.61%
Revenue growth 3Y-5.79%
Revenue growth 5Y10.44%
Sales Q2Q%-43.46%
3.2 Future
The Earnings Per Share is expected to grow by 68.40% on average over the next years. This is a very strong growth
ALPAT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.88% yearly.
EPS Next Y97.01%
EPS Next 2Y68.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.04%
Revenue Next 2Y31.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.81, the valuation of ALPAT can be described as very reasonable.
93.24% of the companies in the same industry are more expensive than ALPAT, based on the Price/Earnings ratio.
ALPAT is valuated cheaply when we compare the Price/Earnings ratio to 27.06, which is the current average of the S&P500 Index.
ALPAT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALPAT is valued a bit cheaper than 79.73% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALPAT indicates a rather cheap valuation: ALPAT is cheaper than 97.30% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.88 | ||
| EV/EBITDA | 17.05 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALPAT has a very decent profitability rating, which may justify a higher PE ratio.
ALPAT's earnings are expected to grow with 68.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y68.4%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALPAT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALPAT (9/5/2025, 7:00:00 PM)
9.08
-0.1 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners33.62%
Ins Owner ChangeN/A
Market Cap10.17M
Analysts84.44
Price Target11.73 (29.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | N/A | ||
| P/S | 5.28 | ||
| P/FCF | 4.88 | ||
| P/OCF | 4.07 | ||
| P/B | 1.08 | ||
| P/tB | 1.77 | ||
| EV/EBITDA | 17.05 |
EPS(TTM)0.84
EY9.25%
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)1.86
FCFY20.5%
OCF(TTM)2.23
OCFY24.55%
SpS1.72
BVpS8.39
TBVpS5.14
PEG (NY)0.11
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.85% | ||
| ROE | 9.95% | ||
| ROCE | 1.98% | ||
| ROIC | 1.41% | ||
| ROICexc | 1.42% | ||
| ROICexgc | 2.12% | ||
| OM | 11.16% | ||
| PM (TTM) | 48.52% | ||
| GM | 116% | ||
| FCFM | 108.17% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.17%
GM growth 5Y-4.76%
F-ScoreN/A
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 73% | ||
| Cap/Sales | 21.4% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 320.17% | ||
| Profit Quality | 222.93% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.3 | ||
| Altman-Z | 0.61 |
F-ScoreN/A
WACC7.26%
ROIC/WACC0.19
Cap/Depr(3y)108.48%
Cap/Depr(5y)137.54%
Cap/Sales(3y)44.29%
Cap/Sales(5y)66.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1057.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.1%
EPS Next Y97.01%
EPS Next 2Y68.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.61%
Revenue growth 3Y-5.79%
Revenue growth 5Y10.44%
Sales Q2Q%-43.46%
Revenue Next Year13.04%
Revenue Next 2Y31.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y128.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.11%
OCF growth 3YN/A
OCF growth 5YN/A